Amarin Corp Plc (AMRN)

[iwfal]

An event driven study where pancreatitis is the endpoint would be tough to do, not possible, TG reduction is the correct basis for efficacy / approval.

The Volanesorsen ph3s indicate that reduction in pancreatitis may actually be the easiest clinical endpoint to hit. Stat sig secondary endpoint in very small trials. FWIW